Proton pump inhibitor deprescription
A rapid review
DOI:
https://doi.org/10.1590/s2175-97902022e19989Keywords:
Proton pump inhibitors, Deprescription, Polypharmacy, Drug-related side effects and adverse reactions, Drug interactionsAbstract
Proton pump inhibitors (PPI) are drugs that suppress gastric acid secretion. Its use, without support from scientific evidence, can contribute to polypharmacy, lead to drug interactions and, in the long term, cause serious adverse reactions. Studies advise physicians to deprescribe PPI. A quick review of scientific evidence, also called a rapid systematic review, on the deprescribing of PPI was performed. Evidence searches were performed in the LILACS, Embase, PubMed and NICE evidence databases with the terms “omeprazole”, “proton pump inhibitors”, “deprescription”, “deprescribing”. At LILACS these descriptors were also used in Portuguese and Spanish. Of 118 studies identified, four systematic reviews were selected for analysis. Abrupt deprescribing was associated with an increased risk of symptom recurrence. Fear of symptom recurrence is one of the major barriers to patient-related deprescribing. Educational interventions directed at prescribers, pharmacists, and patients are effective strategies in the deprescribing of PPI. Deprescribing process showed to be feasible in different contexts, with different strategies. The process is most effective through actions with educational and guidance materials directed to health professionals and patients, and with the involvement or leadership of the pharmacist.
Downloads
References
Ament PW, Dicola DB, James ME. Reducing adverse effects of proton pump inhibitors. Am Fam Physician. 2012;86(1):66-70.
Anthierens S, Tansens A, Petrovic M, Christiaens T. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract. 2010;11:65.
Boghossian TA, Rashid FJ, Thompson W, Welch V, Moayyedi P, Rojas-Fernandez C, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3:CD011969.
Bortoli MC, Setti C, Lima FJS, Dalenogare GV. Mecanismos e programas de revisão rápida. In: Toma TS, Pereira TV, Vanni T, Barreto JOM, organizadores. Avaliação de Tecnologias de Saúde & Políticas Informadas por Evidências. São Paulo, Imprensa Oficial do Estado S/A - IMESP. 2017;105-108
Bundeff AW, Zaiken K. Impact of clinical pharmacists' recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice. J Manag Care Pharm. 2013;19(4):325-33
Chey WD, Mody RR, Izat E. Patient and Physician Satisfaction with Proton Pump Inhibitors (PPIs): Are There Opportunities for Improvement? Dig Dis Sci. 2010;55(12):3415-22.
Chubineh S, Birk J. Proton Pump Inhibitors: The Good, the Bad and the Unwanted. South Med J. 2012;105(11):613-18.
Couteur DL, Banks E, Gnjidic D, McLachlan A. Deprescribing. Australian Prescriber. 2011;34(6):182-85.
Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing Medications for Chronic Diseases Management in Primary Care Settings: A Systematic Review of Randomized Controlled Trials. J Am Med Dir Assoc. 2018;19(11):923-935.
Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017;63(5):354-364.
Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all? World J Gastrointest Pharmacol Ther. 2011;2(3):17-26.
Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28(2):237-53.
Gomes MS, Amorim WW, Morais RS, Gama RS, Graia LT, Queiroga HM, et al. Polypharmacy in older patients at primary care units in Brazil. Int J Clin Pharm. 2019;41(2):516-524.
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol. 2016;73(4):410-6.
Grime JC, Pollock K. How do younger patients view long-term treatment with proton pump inhibitors? J R Soc Promot Health. 2002;122(1):43-9.
Guedes JVM, Aquino JA, Castro TLB, Morais FA, Baldoni AO, Belo VS, et al. Omeprazole use and risk of chronic kidney disease evolution. PLoS One. 2020;15(3):e0229344. Published 2020 Mar 4.
Haastrup P, Paulsen MS, Zwisler JE, Begtrup LM, Hansen JM, Rasmussen S, et al. Rapidly increasing prescribing of proton pump inhibitors in primary care despite interventions: a nationwide observational study. Eur J Gen Pract. 2014;20(4):290-3.
Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85(1):86-8.
Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308-28.
Machado-Alba JE, Gaviria-Mendoza A, Machado-Duque ME, Chica L. Deprescribing: a new goal focused on the patient. Expert Opin Drug Saf. 2017;16(2):111-112.
Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines: A systematic review and meta-analysis. Stroke. 2018;49(2):312-318.
Motter FR, Fritzen JS, Hilmer SN, Paniz ÉV, Paniz VMV. Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharm. 2018;74(6):679-700.
Obreli Neto PR, Nobili A, Marusic S, Pilger D, Guidoni CM, Baldoni AO, et al. Prevalence and predictors of potential drug-drug interactions in the elderly: a cross-sectional study in the brazilian primary public health system. J Pharm Pharm Sci. 2012;15(2):344-354.
Oliveira MG, Amorim WW, de Jesus SR, Rodrigues VA, Passos LC. Factors associated with potentially inappropriate medication use by the elderly in the Brazilian primary care setting. Int J Clin Pharm . 2012;34(4):626-632.
Othman F, Card TR, Crooks CJ. Proton pump inhibitor prescribing patterns in the UK: a primary care database study. Pharmacoepidemiol Drug Saf. 2016;25(9):1079-87.
Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583-623.
Pottegård A, Broe A, Hallas J, Muckadell OBS, Lassen AT, Lødrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therap Adv Gastroenterol. 2016;9(5):671-678.
Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol . 2015;80(6):1254-68.
Reeve E, To J, Hendrix I, Shakib S, Roberts MS, Wiese MD. Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging. 2013;30(10):793-807.
Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80-7.
Santos NS, Marengo LL, Moraes FS, Barberato-Filho S. Interventions to reduce the prescription of inappropriate medicines in older patients. Rev Saude Publica. 2019;53:7.
Sbrafh - Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde [citad 2020 jul 1]. Disponível em: Disponível em: http://www.sbrafh.org.br/inicial/desprescricao/
» http://www.sbrafh.org.br/inicial/desprescricao/
Schoenfeld AJ, Grady D. Adverse Effects Associated With Proton Pump Inhibitors. JAMA Intern Med. 2016;176(2):172-4.
Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med . 2015;175(5):827-34.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
Smeets HM, De Wit NJ, Delnoij DM, Hoes AW. Patient attitudes towards and experiences with an intervention programme to reduce chronic acid-suppressing drug intake in primary care. Eur J Gen Pract . 2009;15(4):219-25.
Spijker-Huiges A, Winters JC, Meyboom-De Jong B. Patients' views on dyspepsia and acid suppressant drug therapy in general practice. Eur J Gen Pract . 2006;12(1):10-4.
Thompson W, Black C, Welch V, Farrell B, Bjerre LM, Tugwell P. Patient Values and Preferences Surrounding Proton Pump Inhibitor Use: A Scoping Review. Patient. 2018;11(1):17-28.
Wallace JL, Sharkey KA. Farmacoterapia da acidez gástrica, úlceras pépticas e doença do refluxo gastroesofágico. In: Brunton LL, Chabiner BA, Knollmann BC, organizadores. As Bases Farmacológicas da Terapêutica de Goodman & Gilman - 12a edição. Porto Alegre. AMGH Editora LTDA. 2012. p. 1309-22.
Walsh K, Kwan D, Marr P, Papoushek C, Lyon WK. Deprescribing in a family health team: a study of chronic proton pump inhibitor use. J Prim Health Care. 2016;8(2):164-71.
Wilsdon TD, Hendrix I, Thynne TR, Mangoni AA. Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults. Drugs Aging. 2017;34(4):265-287.
Woodward MC. Deprescribing: Achieving Better Health Outcomes for Older People Through Reducing Medications. J Pharm Pract Res. 2003;33(4):323-28.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
